As per the agreement, the companies are expected to study short interfering RNA (siRNA) complexed to PTD-DRBD, with the ultimate goal of developing drugs using this technology.
Hans Petersen, president and CEO of Traversa, said: “We are thrilled to be working with the high caliber global team of Sanofi-aventis, and look forward to successful research collaboration.
“This agreement will allow Sanofi-aventis to select lead RNAi candidates and provide Traversa with a better understanding of the strengths of our RNAi delivery technology. We are excited to be working with Sanofi-aventis to conduct this research, and hope to advance the treatments selected during this collaboration into IND-enabling studies and into the clinics.”